Biogen Inc. Logo

Biogen Inc. (BIIB)

SIX

Currency in CHF
173.46
0.00 (0.00%)

Real-time Data

07:00 AM

Day's Range

173.46
173.46

52 wk Range

131.09
232.00

Overview - BIIB - Biogen Inc.

Key Statistics

Valuation

Enterprise Value

27.15B

P/E (Trailing)

‪30.79‬

PEG Ratio

‪-0.36‬

Price / Sales (TTM)

‪2.07‬

Price / Book

‪1.36‬

EV / EBITDA

‪9.97‬

Profitability

Gross Margin

‪71.60%‬

Profit Margin

‪8.32%‬

Operating Margin

‪25.05%‬

Return on Assets

‪5.20%‬

Return on Equity

‪4.57%‬

Ownership

Shares Outstanding

147.70M

Float

147.29M

Held by Insiders

‪0.18%‬

Held by Institutions

‪96.35%‬

Price stats

Beta

‪0.16‬

50-Day Avg

‪165.07‬

200-Day Avg

‪153.84‬

Dividends

Payout Ratio

‪0.00%‬

Shariah Compliance

Not Shariah Compliant

Report Date: Feb 16, 2025

Screened by Zoya using the AAOIFI methodology.

Peers - BIIB - Biogen Inc.

Peer Comparison

Compared with companies in Drug Manufacturers - General listed on SIX.

Profile Summary - BIIB - Biogen Inc.

About

Biogen Inc. is a biotechnology company that discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company offers products such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for…

SectorHealthcare
IndustryDrug Manufacturers - General
Employees7.50K
Full company profile

The information on this page is provided for general informational purposes only and is not investment advice.

Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.

Last updated:

Stocks news

Track Global Markets in Real Time with UA Finance

Download the app now and access live financial data, expert analysis, and trusted economic news to follow stocks, forex, gold, and cryptocurrencies with ease.